跳轉至內容
Merck
全部照片(1)

Key Documents

B0760

Supelco

丁苯羟酸

analytical standard

同義詞:

对丁氧苯乙酰氧肟酸

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C12H17NO3
CAS號碼:
分子量::
223.27
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

格式

neat

SMILES 字串

CCCCOc1ccc(CC(=O)NO)cc1

InChI

1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)

InChI 密鑰

MXJWRABVEGLYDG-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

Bufexamac is a drug with antipyretic, analgesic and anti-inflammatory properties.

應用

Bufexamac may be used as a reference standard in the determination of bufexamac in pharmaceutical formulations using high-performance liquid chromatography (HPLC).
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

推薦產品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

P H Marttinen et al.
Journal of veterinary medicine. A, Physiology, pathology, clinical medicine, 53(6), 311-318 (2006-08-12)
The objective here was to evaluate the acute effects of induced arthritis on synovial fluid (SF) levels of matrix metalloproteinases (MMP) -2, -8 and -9 in horses. To evaluate MMP-2 and -9 activities and the effect of non-steroidal anti-inflammatory drug
Ritu Gupta et al.
The Australasian journal of dermatology, 47(2), 117-119 (2006-04-28)
A 24-year-old woman had a 9-week history of second to third daily urticaria that began after an episode of contact urticaria to topical bufexamac. She was found to have an underlying gastrointestinal infection with Blastocystis hominis. This was thought to
K Waltermann et al.
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 60(5), 424-427 (2008-12-19)
We report on a case of a bufexamac-induced allergic contact dermatitis with hematogenous dissemination presenting with the clinical and histological picture of a pigmented purpuric eruption. To our knowledge this is the first report on a bufexamac-induced pigmented purpuric dermatosis.
Hagen Trommer et al.
The Journal of pharmacy and pharmacology, 55(10), 1379-1388 (2003-11-11)
The effect of bufexamac on UV-irradiation-induced lipid peroxidation was investigated. Linolenic acid was used as a model lipid. Bufexamac was shown to be capable of reducing the amount of lipid peroxidation. The quantification was carried out by the thiobarbituric acid
Contact sensitivity to bufexamac.
Lachapelle JM.
Contact Dermatitis, 1(4), 261-261 (1975)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務